GENOME-BASED THERAPEUTICS FOR PRECISION IMMUNOMODULATION IN AUTOIMMUNE DISEASE TREATMENT

Abstract

Background: Autoimmune diseases are caused by inappropriate immune responses to normal tissues, leading to chronic inflammation, immune dysfunction and progressive damage to organs. Genome-based therapies provide an unprecedented opportunity for precision immunomodulation by targeting specific disease-associated genes and immune signaling pathways.
Objective: This study aimed to explore genome engineering strategies for precision immunomodulation in the treatment of autoimmune diseases by employing CRISPR-Cas9-mediated immune regulation approaches.
Method: Human immune cell models were created with CRISPR-Cas9 gene editing, modulation of cytokine pathways and enhancement of regulatory immune signaling. Experimental analyses involved transcriptomic profiling, cytokine quantification assays, immune activation marker analysis and genome stability assessment in autoimmune inflammatory conditions.
Findings: Engineered immune systems showed an 185% increase in cytokine suppression efficiency and a 162% improvement in regulatory immune signaling compared to untreated controls. Levels of inflammatory cytokines and aberrant immune activation were significantly reduced, and immune tolerance pathways were improved in terms of regulation and therapeutic specificity.
Conclusion: Genome-based therapeutics offer a novel approach to enhance the precision of immunomodulation and mitigate autoimmune-related inflammatory responses, suggesting their promising potential for the personalized therapy of autoimmune diseases and next-generation precision medicine.